{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T17:58:46Z","timestamp":1787162326760,"version":"build-2736575974"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2012,7,12]],"date-time":"2012-07-12T00:00:00Z","timestamp":1342051200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Curr Neurol Neurosci Rep"],"published-print":{"date-parts":[[2012,10]]},"DOI":"10.1007\/s11910-012-0294-3","type":"journal-article","created":{"date-parts":[[2012,7,11]],"date-time":"2012-07-11T09:08:22Z","timestamp":1341997702000},"page":"618-627","source":"Crossref","is-referenced-by-count":46,"title":["Cognitive Impairment in Multiple Sclerosis"],"prefix":"10.1007","volume":"12","author":[{"given":"Jesus","family":"Lovera","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Blake","family":"Kovner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2012,7,12]]},"reference":[{"key":"294_CR1","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1038\/nrneurol.2011.61","volume":"7","author":"RH Benedict","year":"2011","unstructured":"\u2022 Benedict RH, Zivadinov R. Risk factors for and management of cognitive dysfunction in multiple sclerosis. Nat Rev Neurol. 2011;7:332\u201342. Important recent review on CI in MS.","journal-title":"Nat Rev Neurol"},{"key":"294_CR2","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/j.ncl.2010.12.003","volume":"29","author":"LJ Julian","year":"2011","unstructured":"\u2022 Julian LJ. Cognitive functioning in multiple sclerosis. Neurol Clin. 2011;29:507\u201325. Important recent review on CI in MS.","journal-title":"Neurol Clin"},{"key":"294_CR3","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1212\/WNL.41.5.685","volume":"41","author":"SM Rao","year":"1991","unstructured":"Rao SM, Leo GJ, Bernardin L, Unverzagt F. Cognitive dysfunction in multiple sclerosis: I. Frequency, patterns, and prediction. Neurology. 1991;41:685\u201391.","journal-title":"Neurology"},{"key":"294_CR4","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1076\/clin.16.3.381.13859","volume":"16","author":"RH Benedict","year":"2002","unstructured":"Benedict RH, Fischer JS, Archibald CJ, et al. Minimal neuropsychological assessment of MS patients: a consensus approach. Clin Neuropsychol. 2002;16:381\u201397.","journal-title":"Clin Neuropsychol"},{"key":"294_CR5","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1111\/j.1468-1331.2009.02836.x","volume":"17","author":"M Banati","year":"2009","unstructured":"Banati M, Sandor J, Mike A, et al. Social cognition and theory of mind in patients with relapsing\u2013remitting multiple sclerosis. Eur J Neurol. 2009;17:426\u201333.","journal-title":"Eur J Neurol"},{"key":"294_CR6","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1007\/s11682-011-9128-1","volume":"5","author":"M Jehna","year":"2011","unstructured":"\u2022 Jehna M, Langkammer C, Wallner-Blazek M, et al. Cognitively preserved MS patients demonstrate functional differences in processing neutral and emotional faces. Brain Imaging Behav. 2011;5:241\u201351. Interesting new findings on the changes in cortical networks responsible theory of mind processes in patients with MS.","journal-title":"Brain Imaging Behav"},{"key":"294_CR7","doi-asserted-by":"crossref","first-page":"1602","DOI":"10.1001\/archneur.58.10.1602","volume":"58","author":"MP Amato","year":"2001","unstructured":"Amato MP, Ponziani G, Siracusa G, Sorbi S. Cognitive dysfunction in early-onset multiple sclerosis: a reappraisal after 10 years. Arch Neurol. 2001;58:1602\u20136.","journal-title":"Arch Neurol"},{"key":"294_CR8","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1080\/13854046.2010.511272","volume":"24","author":"SA Morrow","year":"2010","unstructured":"\u2022 Morrow SA, Drake A, Zivadinov R, et al. Predicting loss of employment over three years in multiple sclerosis: clinically meaningful cognitive decline. Clin Neuropsychol. 2010;24:1131\u201345. This important paper helps determine a level of change in cognitive tests that has important implications for employability and will be useful in the design of clinical trials.","journal-title":"Clin Neuropsychol"},{"key":"294_CR9","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.jns.2012.02.003","volume":"316","author":"VL D'Orio","year":"2012","unstructured":"D'Orio VL, Foley FW, Armentano F, et al. Cognitive and motor functioning in patients with multiple sclerosis: neuropsychological predictors of walking speed and falls. J Neurol Sci. 2012;316:42\u20136.","journal-title":"J Neurol Sci"},{"key":"294_CR10","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1002\/1531-8249(200012)48:6<885::AID-ANA9>3.0.CO;2-1","volume":"48","author":"JS Fischer","year":"2000","unstructured":"Fischer JS, Priore RL, Jacobs LD, et al. Neuropsychological effects of interferon beta-1a in relapsing multiple sclerosis. Multiple Sclerosis Collaborative Research Group. Ann Neurol. 2000;48:885\u201392.","journal-title":"Ann Neurol"},{"key":"294_CR11","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1212\/WNL.47.6.1463","volume":"47","author":"NH Pliskin","year":"1996","unstructured":"Pliskin NH, Hamer DP, Goldstein DS, et al. Improved delayed visual reproduction test performance in multiple sclerosis patients receiving interferon beta-1b. Neurology. 1996;47:1463\u20138.","journal-title":"Neurology"},{"key":"294_CR12","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1212\/01.WNL.0000146958.77317.3E","volume":"63","author":"H Panitch","year":"2004","unstructured":"Panitch H, Miller A, Paty D, Weinshenker B. Interferon beta-1b in secondary progressive MS: results from a 3-year controlled study. Neurology. 2004;63:1788\u201395.","journal-title":"Neurology"},{"key":"294_CR13","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1001\/archneur.56.3.319","volume":"56","author":"A Weinstein","year":"1999","unstructured":"Weinstein A, Schwid SR, Schiffer RB, et al. Neuropsychologic status in multiple sclerosis after treatment with glatiramer. Arch Neurol. 1999;56:319\u201324.","journal-title":"Arch Neurol"},{"key":"294_CR14","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1056\/NEJMoa044397","volume":"354","author":"CH Polman","year":"2006","unstructured":"Polman CH, O\u2019Connor PW, Havrdova E, et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med. 2006;354:899\u2013910.","journal-title":"N Engl J Med"},{"key":"294_CR15","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1056\/NEJMoa044396","volume":"354","author":"RA Rudick","year":"2006","unstructured":"Rudick RA, Stuart WH, Calabresi PA, et al. Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. N Engl J Med. 2006;354:911\u201323.","journal-title":"N Engl J Med"},{"key":"294_CR16","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1007\/s00415-011-6275-7","volume":"259","author":"B Weinstock-Guttman","year":"2012","unstructured":"\u2022 Weinstock-Guttman B, Galetta SL, Giovannoni G, et al. Additional efficacy endpoints from pivotal natalizumab trials in relapsing-remitting MS. J Neurol. 2012;259:898\u2013905. Important although limited assessment of the impact of Natalizumab on CI.","journal-title":"J Neurol"},{"key":"294_CR17","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1159\/000334722","volume":"67","author":"C Lang","year":"2012","unstructured":"Lang C, Reiss C, Maurer M. Natalizumab may improve cognition and mood in multiple sclerosis. Eur Neurol. 2012;67:162\u20136.","journal-title":"Eur Neurol"},{"key":"294_CR18","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/s10072-010-0412-4","volume":"32","author":"F Mattioli","year":"2011","unstructured":"Mattioli F, Stampatori C, Capra R. The effect of natalizumab on cognitive function in patients with relapsing-remitting multiple sclerosis: preliminary results of a 1-year follow-up study. Neurol Sci. 2011;32:83\u20138.","journal-title":"Neurol Sci"},{"key":"294_CR19","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1177\/1352458510378021","volume":"16","author":"SA Morrow","year":"2010","unstructured":"Morrow SA, O\u2019Connor PW, Polman CH, et al. Evaluation of the symbol digit modalities test (SDMT) and MS neuropsychological screening questionnaire (MSNQ) in natalizumab-treated MS patients over 48 weeks. Mult Scler. 2010;16:1385\u201392.","journal-title":"Mult Scler"},{"issue":"5","key":"294_CR20","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1056\/NEJMoa0907839","volume":"362","author":"JA Cohen","year":"2010","unstructured":"Cohen JA, Barkhof F, Comi G, et al. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med. 2010;362(5):402\u201315.","journal-title":"N Engl J Med"},{"key":"294_CR21","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1056\/NEJMoa0909494","volume":"362","author":"L Kappos","year":"2010","unstructured":"Kappos L, Radue EW, O'Connor P, et al. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med. 2010;362:387\u2013401.","journal-title":"N Engl J Med"},{"key":"294_CR22","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.jns.2007.01.070","volume":"255","author":"SR Schwid","year":"2007","unstructured":"Schwid SR, Goodman AD, Weinstein A, et al. Cognitive function in relapsing multiple sclerosis: minimal changes in a 10-year clinical trial. J Neurol Sci. 2007;255:57\u201363.","journal-title":"J Neurol Sci"},{"key":"294_CR23","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1177\/1352458509350309","volume":"16","author":"F Patti","year":"2009","unstructured":"Patti F, Amato MP, Bastianello S, et al. Effects of immunomodulatory treatment with subcutaneous interferon beta-1a on cognitive decline in mildly disabled patients with relapsing\u2013remitting multiple sclerosis. Mult Scler. 2009;16:68\u201377.","journal-title":"Mult Scler"},{"key":"294_CR24","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1177\/1352458508089686","volume":"14","author":"B Duque","year":"2008","unstructured":"Duque B, Sepulcre J, Bejarano B, et al. Memory decline evolves independently of disease activity in MS. Mult Scler. 2008;14:947\u201353.","journal-title":"Mult Scler"},{"key":"294_CR25","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1590\/S0004-282X2011000700007","volume":"69","author":"JB Brooks","year":"2012","unstructured":"Brooks JB, Borela MC, Fragoso YD. Assessment of cognition using the Rao's Brief Repeatable Battery of Neuropsychological Tests on a group of Brazilian patients with multiple sclerosis. Arq Neuropsiquiatr. 2012;69:887\u201391.","journal-title":"Arq Neuropsiquiatr"},{"key":"294_CR26","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/1471-2377-11-17","volume":"11","author":"K Baumstarck-Barrau","year":"2011","unstructured":"Baumstarck-Barrau K, Simeoni MC, Reuter F, et al. Cognitive function and quality of life in multiple sclerosis patients: a cross-sectional study. BMC Neurol. 2011;11:17.","journal-title":"BMC Neurol"},{"key":"294_CR27","doi-asserted-by":"crossref","unstructured":"Brissart H, Morele E, Baumann C, Debouverie M. Verbal episodic memory in 426 multiple sclerosis patients: impairment in encoding, retrieval or both? Neurol Sci. 2012.","DOI":"10.1007\/s10072-011-0915-7"},{"key":"294_CR28","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1136\/jnnp.2010.237834","volume":"83","author":"BI Glanz","year":"2011","unstructured":"Glanz BI, Healy BC, Hviid LE, et al. Cognitive deterioration in patients with early multiple sclerosis: a 5-year study. J Neurol Neurosurg Psychiatry. 2011;83:38\u201343.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"294_CR29","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1177\/1352458506071196","volume":"13","author":"L Feuillet","year":"2007","unstructured":"Feuillet L, Reuter F, Audoin B, et al. Early cognitive impairment in patients with clinically isolated syndrome suggestive of multiple sclerosis. Mult Scler. 2007;13:124\u20137.","journal-title":"Mult Scler"},{"key":"294_CR30","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1007\/s10072-008-1020-4","volume":"29","author":"B Kocer","year":"2008","unstructured":"Kocer B, Unal T, Nazliel B, et al. Evaluating sub-clinical cognitive dysfunction and event-related potentials (P300) in clinically isolated syndrome. Neurol Sci. 2008;29:435\u201344.","journal-title":"Neurol Sci"},{"key":"294_CR31","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1136\/jnnp.55.10.869","volume":"55","author":"A Feinstein","year":"1992","unstructured":"Feinstein A, Kartsounis LD, Miller DH, et al. Clinically isolated lesions of the type seen in multiple sclerosis: a cognitive, psychiatric, and MRI follow up study. J Neurol Neurosurg Psychiatry. 1992;55:869\u201376.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"294_CR32","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1136\/jnnp.2010.213744","volume":"82","author":"F Reuter","year":"2010","unstructured":"Reuter F, Zaaraoui W, Crespy L, et al. Frequency of cognitive impairment dramatically increases during the first 5 years of multiple sclerosis. J Neurol Neurosurg Psychiatry. 2010;82:1157\u20139.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"294_CR33","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1177\/1352458510375707","volume":"16","author":"C Lebrun","year":"2010","unstructured":"\u2022 Lebrun C, Blanc F, Brassat D, et al. Cognitive function in radiologically isolated syndrome. Mult Scler. 2010;16:919\u201325. This interesting study documents the presence of cognitive changes before other symptoms occur among people with incidental findings of brain lesions typical of MS.","journal-title":"Mult Scler"},{"key":"294_CR34","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1212\/WNL.0b013e31824528c9","volume":"78","author":"MP Amato","year":"2012","unstructured":"\u2022 Amato MP, Hakiki B, Goretti B, et al. Association of MRI metrics and cognitive impairment in radiologically isolated syndromes. Neurology. 2012;78:309\u201314. Another recent interesting study documenting CI in patients with RIS.","journal-title":"Neurology"},{"key":"294_CR35","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1212\/WNL.0b013e31824d5859","volume":"78","author":"S Mesaros","year":"2012","unstructured":"\u2022 Mesaros S, Rocca MA, Kacar K, et al. Diffusion tensor MRI tractography and cognitive impairment in multiple sclerosis. Neurology. 2012;78:969\u201375. This study clarifies the long-standing paradox of why lesion burden does not correlate with CI.","journal-title":"Neurology"},{"key":"294_CR36","doi-asserted-by":"crossref","first-page":"19066","DOI":"10.1073\/pnas.1110024108","volume":"108","author":"DJ Hawellek","year":"2011","unstructured":"\u2022 Hawellek DJ, Hipp JF, Lewis CM, et al. Increased functional connectivity indicates the severity of cognitive impairment in multiple sclerosis. Proc Natl Acad Sci U S A. 2011;108:19066\u201371. This study documents changes in the default and control networks in patients with MS and correlates these changes with CI.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"294_CR37","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1177\/1352458510375440","volume":"16","author":"F Fink","year":"2010","unstructured":"Fink F, Rischkau E, Butt M, et al. Efficacy of an executive function intervention programme in MS: a placebo-controlled and pseudo-randomized trial. Mult Scler. 2010;16:1148\u201351.","journal-title":"Mult Scler"},{"key":"294_CR38","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1191\/1352458505ms1118oa","volume":"11","author":"ND Chiaravalloti","year":"2005","unstructured":"Chiaravalloti ND, DeLuca J, Moore NB, Ricker JH. Treating learning impairments improves memory performance in multiple sclerosis: a randomized clinical trial. Mult Scler. 2005;11:58\u201368.","journal-title":"Mult Scler"},{"key":"294_CR39","doi-asserted-by":"crossref","unstructured":"\u2022 Stuifbergen AK, Becker H, Perez F, et al. A randomized controlled trial of a cognitive rehabilitation intervention for persons with multiple sclerosis. Clin Rehabil. 2012. This study shows promising results from cognitive rehabilitation strategy.","DOI":"10.1177\/0269215511434997"},{"key":"294_CR40","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.jns.2008.08.025","volume":"276","author":"Y Harel","year":"2009","unstructured":"Harel Y, Appleboim N, Lavie M, Achiron A. Single dose of methylphenidate improves cognitive performance in multiple sclerosis patients with impaired attention process. J Neurol Sci. 2009;276:38\u201340.","journal-title":"J Neurol Sci"},{"key":"294_CR41","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1007\/s00415-008-0760-7","volume":"255","author":"RH Benedict","year":"2008","unstructured":"Benedict RH, Munschauer F, Zarevics P, et al. Effects of l-amphetamine sulfate on cognitive function in multiple sclerosis patients. J Neurol. 2008;255:848\u201352.","journal-title":"J Neurol"},{"key":"294_CR42","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1177\/1352458511404585","volume":"17","author":"JF Sumowski","year":"2011","unstructured":"Sumowski JF, Chiaravalloti N, Erlanger D, et al. L-amphetamine improves memory in MS patients with objective memory impairment. Mult Scler. 2011;17:1141\u20135.","journal-title":"Mult Scler"},{"key":"294_CR43","doi-asserted-by":"crossref","first-page":"1","DOI":"10.7224\/1537-2073-10.1.1","volume":"10","author":"JA Wilken","year":"2008","unstructured":"Wilken JA, Sulliven C, Wallin M, et al. Treatment of multiple sclerosis\u2013related cognitive problems with adjunctive modafinil. Int J MS Care. 2008;10:1\u201310.","journal-title":"Int J MS Care"},{"key":"294_CR44","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1177\/1352458511402410","volume":"17","author":"F Moller","year":"2011","unstructured":"Moller F, Poettgen J, Broemel F, et al. HAGIL (Hamburg Vigil Study): a randomized placebo-controlled double-blind study with modafinil for treatment of fatigue in patients with multiple sclerosis. Mult Scler. 2011;17:1002\u20139.","journal-title":"Mult Scler"},{"key":"294_CR45","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1177\/1352458511412061","volume":"17","author":"S Huolman","year":"2011","unstructured":"Huolman S, Hamalainen P, Vorobyev V, et al. The effects of rivastigmine on processing speed and brain activation in patients with multiple sclerosis and subjective cognitive fatigue. Mult Scler. 2011;17:1351\u201361.","journal-title":"Mult Scler"},{"key":"294_CR46","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1212\/01.WNL.0000142989.09633.5A","volume":"63","author":"LB Krupp","year":"2004","unstructured":"Krupp LB, Christodoulou C, Melville P, et al. Donepezil improved memory in multiple sclerosis in a randomized clinical trial. Neurology. 2004;63:1579\u201385.","journal-title":"Neurology"},{"key":"294_CR47","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1212\/WNL.0b013e318218107a","volume":"76","author":"LB Krupp","year":"2011","unstructured":"\u2022 Krupp LB, Christodoulou C, Melville P, et al. Multicenter randomized clinical trial of donepezil for memory impairment in multiple sclerosis. Neurology. 2011;76:1500\u20137. This is an important randomized placebo-controlled trial that, unfortunately, showed no benefit with donepezil.","journal-title":"Neurology"},{"key":"294_CR48","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1212\/01.wnl.0000342388.73185.80","volume":"72","author":"P Villoslada","year":"2009","unstructured":"Villoslada P, Arrondo G, Sepulcre J, et al. Memantine induces reversible neurologic impairment in patients with MS. Neurology. 2009;72:1630\u20133.","journal-title":"Neurology"},{"key":"294_CR49","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1177\/1352458510367662","volume":"16","author":"JF Lovera","year":"2010","unstructured":"\u2022 Lovera JF, Frohman E, Brown TR, et al. Memantine for cognitive impairment in multiple sclerosis: a randomized placebo-controlled trial. Mult Scler. 2010;16:715\u201323. Our randomized multicenter trial with memantine also failed to show any beneficial effect.","journal-title":"Mult Scler"},{"key":"294_CR50","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1177\/1352458506071213","volume":"13","author":"J Lovera","year":"2007","unstructured":"Lovera J, Bagert B, Smoot K, et al. Ginkgo biloba for the improvement of cognitive performance in multiple sclerosis: a randomized, placebo-controlled trial. Mult Scler. 2007;13:376\u201385.","journal-title":"Mult Scler"},{"key":"294_CR51","unstructured":"Lovera J, Howieson D, Wild K, et al. Randomized placebo controlled trial of Ginkgo biloba for cognitive impairment in multiple sclerosis. Neurology 2011 Suppl 4: A546"},{"key":"294_CR52","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1123\/jsep.33.5.734","volume":"33","author":"RW Motl","year":"2011","unstructured":"Motl RW, Gappmaier E, Nelson K, Benedict RH. Physical activity and cognitive function in multiple sclerosis. J Sport Exerc Psychol. 2011;33:734\u201341.","journal-title":"J Sport Exerc Psychol"},{"key":"294_CR53","doi-asserted-by":"crossref","first-page":"2058","DOI":"10.1212\/01.WNL.0000129534.88602.5C","volume":"62","author":"BS Oken","year":"2004","unstructured":"Oken BS, Kishiyama S, Zajdel D, et al. Randomized controlled trial of yoga and exercise in multiple sclerosis. Neurology. 2004;62:2058\u201364.","journal-title":"Neurology"}],"container-title":["Current Neurology and Neuroscience Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11910-012-0294-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11910-012-0294-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11910-012-0294-3","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,30]],"date-time":"2019-06-30T16:44:19Z","timestamp":1561913059000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11910-012-0294-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,7,12]]},"references-count":53,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2012,10]]}},"alternative-id":["294"],"URL":"https:\/\/doi.org\/10.1007\/s11910-012-0294-3","relation":{},"ISSN":["1528-4042","1534-6293"],"issn-type":[{"value":"1528-4042","type":"print"},{"value":"1534-6293","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,7,12]]}}}